This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Markers of remodelling in dilated cardiomyopathy

  • Research type

    Research Study

  • Full title

    The REMIT-DCM study: Reverse rEmodelling Markers In the serial evaluation of recenT-onset Dilated CardioMyopathy

  • IRAS ID

    262962

  • Contact name

    Sanjay Prasad

  • Contact email

    s.prasad@rbht.nhs.uk

  • Sponsor organisation

    Imperial College London

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    Dilated cardiomyopathy (DCM) is a disease of the heart muscle that often affects young people. It causes the heart to become enlarged and the heart muscle to become weakened. In approximately a third of cases of DCM, the enlarged and weakened heart will significantly improve. This is associated with better health outcomes in the longer term. Doctors currently are not able to accurately predict which patients with DCM will undergo this improvement and which will not.

    In this observational cohort study of patients with recent-onset DCM, we will closely observe patients with DCM during the process of heart muscle remodelling and contrast our findings with healthy subjects who do not have heart disease. We will study 60 patients with recent-onset DCM over a 12-month period. We will measure blood protein levels and blood and urine levels of the products of chemical reactions called metabolites. These will be measured at three time points during the process of heart remodelling (at the first visit, 2-3 months later and 12 months after the first visit). We will assess the degree of improvement of the heart function by performing specialist heart scans called cardiovascular magnetic resonance (CMR).

    By combining the information from the specialist blood and urine tests with CMRs, we hope to develop a more in-depth understanding of the why some patients with DCM improve. We are seeking to find new markers of improvement in heart function. We hope to identify methods to predict which patients will improve and which will not. This could facilitate the delivery of more personalised care for patients with DCM. It is also possible that understanding the chemical pathways involved in this process may help to develop new drug treatments for DCM.

  • REC name

    London - Queen Square Research Ethics Committee

  • REC reference

    19/LO/1014

  • Date of REC Opinion

    12 Jul 2019

  • REC opinion

    Further Information Favourable Opinion